Insidious dopamine: provocateur or protective agent in Parkinson's disease?
Kostrzewa
R M
RM
Department of Pharmacology, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, USA.
Brus
R
R
Kostrzewa
J P
JP
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D017382:Reactive Oxygen Species / Q000378:metabolism
D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D017382:Reactive Oxygen Species; D007980:Levodopa; D004298:Dopamine